Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Eastside Medical Center
1938
mi
from 91732
Snellville, GA
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Eastside Medical Center
1938
mi
from 91732
Snellville, GA
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Medical City McKinney - Solis Mammography
mi
from 91732
McKinney, TX
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Medical City McKinney - Solis Mammography
mi
from 91732
McKinney, TX
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Breast Imaging Henry Ford Medical Center Fairlane
mi
from 91732
Dearborn, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Breast Imaging Henry Ford Medical Center Fairlane
mi
from 91732
Dearborn, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center, New Center One
1965
mi
from 91732
Detroit, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center, New Center One
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center Cottage
mi
from 91732
Grosse Pointe Farms, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center Cottage
mi
from 91732
Grosse Pointe Farms, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Livonia Medical Center
mi
from 91732
Livonia, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Livonia Medical Center
mi
from 91732
Livonia, MI
Click here to add this to my saved trials
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
2410
mi
from 91732
New Brunswick, NJ
Click here to add this to my saved trials
Susceptibility to Breast Cancer
Susceptibility to Breast Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Susceptibility to Breast Cancer
Susceptibility to Breast Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study
Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study
Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
The Incidence of Breast and Other Cancers Among Female Flight Attendants
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Status: Enrolling
Updated:  12/31/1969
National Institute for Occupational Safety and Health (NIOSH)
1882
mi
from 91732
Cincinnati, OH
The Incidence of Breast and Other Cancers Among Female Flight Attendants
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Status: Enrolling
Updated: 12/31/1969
National Institute for Occupational Safety and Health (NIOSH)
1882
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, School of Public Health Environmental Health Sciences
1511
mi
from 91732
Minneapolis, MN
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, School of Public Health Environmental Health Sciences
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Herald Cancer Association
4
mi
from 91732
Los Angeles, CA
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Herald Cancer Association
4
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
University of Houston
1355
mi
from 91732
Houston, TX
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
University of Houston
1355
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ttuhsc
689
mi
from 91732
El Paso, TX
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ttuhsc
689
mi
from 91732
El Paso, TX
Click here to add this to my saved trials
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2159
mi
from 91732
Toronto,
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2159
mi
from 91732
Toronto,
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
26
mi
from 91732
Santa Monica, CA
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
26
mi
from 91732
Santa Monica, CA
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis
2435
mi
from 91732
New York, NY
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
Community Hospital Identification of High CV Risk Patients During Cancer Treatment (CHI)
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
2129
mi
from 91732
Winston-Salem, NC
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
Community Hospital Identification of High CV Risk Patients During Cancer Treatment (CHI)
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
2129
mi
from 91732
Winston-Salem, NC
Click here to add this to my saved trials
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
686
mi
from 91732
El Paso, TX
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
686
mi
from 91732
El Paso, TX
Click here to add this to my saved trials
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
5613
mi
from 91732
Leuven,
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
5613
mi
from 91732
Leuven,
Click here to add this to my saved trials
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
2434
mi
from 91732
New York, NY
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
2434
mi
from 91732
New York, NY
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Ironwood Cancer and Research Centers
356
mi
from 91732
Chandler, AZ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Ironwood Cancer and Research Centers
356
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Beverly Hills Cancer Center
21
mi
from 91732
Beverly Hills, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Beverly Hills Cancer Center
21
mi
from 91732
Beverly Hills, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Ventura County Hematology and Oncology
67
mi
from 91732
Oxnard, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Ventura County Hematology and Oncology
67
mi
from 91732
Oxnard, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Research Institute Dept of Oncology
2311
mi
from 91732
Davie, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Research Institute Dept of Oncology
2311
mi
from 91732
Davie, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Watson Clinic Center for Research 1730 Location
2162
mi
from 91732
Lakeland, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Watson Clinic Center for Research 1730 Location
2162
mi
from 91732
Lakeland, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
John D. Archbold Memorial Hospital John D. Archbold Mem Hosp (4)
1988
mi
from 91732
Thomasville, GA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
John D. Archbold Memorial Hospital John D. Archbold Mem Hosp (4)
1988
mi
from 91732
Thomasville, GA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Joliet Oncology-Hematology Associates Presence Cancer Center
1699
mi
from 91732
Joliet, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Joliet Oncology-Hematology Associates Presence Cancer Center
1699
mi
from 91732
Joliet, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Englewood Hospital and Medical Center
2433
mi
from 91732
Englewood, NJ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Englewood Hospital and Medical Center
2433
mi
from 91732
Englewood, NJ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
PeaceHealth St. Joseph Medical Center
1039
mi
from 91732
Bellingham, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
PeaceHealth St. Joseph Medical Center
1039
mi
from 91732
Bellingham, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Providence Regional Medical Centre of Everett
986
mi
from 91732
Everett, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Providence Regional Medical Centre of Everett
986
mi
from 91732
Everett, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties Dept.ofNW Med. Specialties
939
mi
from 91732
Tacoma, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties Dept.ofNW Med. Specialties
939
mi
from 91732
Tacoma, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3)
870
mi
from 91732
Cheyenne, WY
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3)
870
mi
from 91732
Cheyenne, WY
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates Arizona Oncology Assoc. (2)
425
mi
from 91732
Tucson, AZ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates Arizona Oncology Assoc. (2)
425
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
1354
mi
from 91732
Fayetteville, AR
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
1354
mi
from 91732
Fayetteville, AR
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Shores Medical Group SC
22
mi
from 91732
Long Beach, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Shores Medical Group SC
22
mi
from 91732
Long Beach, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
PCR Oncology
166
mi
from 91732
Pismo Beach, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
PCR Oncology
166
mi
from 91732
Pismo Beach, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Centura Health Research Center Centura Health Research Center
816
mi
from 91732
Denver, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Centura Health Research Center Centura Health Research Center
816
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital Poudre Valley Health System
839
mi
from 91732
Fort Collins, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital Poudre Valley Health System
839
mi
from 91732
Fort Collins, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Valley View Hospital Cancer Center
700
mi
from 91732
Glenwood Springs, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Valley View Hospital Cancer Center
700
mi
from 91732
Glenwood Springs, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Mid Florida Hematology and Oncology Center
2181
mi
from 91732
Orange City, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Mid Florida Hematology and Oncology Center
2181
mi
from 91732
Orange City, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Summit Cancer Care Summit Cancer Care (SC)
2130
mi
from 91732
Savannah, GA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Summit Cancer Care Summit Cancer Care (SC)
2130
mi
from 91732
Savannah, GA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Regional Medical Center
664
mi
from 91732
Boise, ID
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Regional Medical Center
664
mi
from 91732
Boise, ID
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)
1647
mi
from 91732
Normal, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)
1647
mi
from 91732
Normal, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Alpha Med Physician Group, LLC
1715
mi
from 91732
Tinley Park, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Alpha Med Physician Group, LLC
1715
mi
from 91732
Tinley Park, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center for Cancer SC
1819
mi
from 91732
Goshen, IN
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center for Cancer SC
1819
mi
from 91732
Goshen, IN
Click here to add this to my saved trials